Kenvue Inc. (NYSE:KVUE) Receives Consensus Rating of “Hold” from Analysts

Kenvue Inc. (NYSE:KVUE) has been given a consensus recommendation of “Hold” by the sixteen research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $24.85.

Several research analysts have commented on KVUE shares. Royal Bank of Canada lowered their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. JPMorgan Chase & Co. lowered their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 9th. The Goldman Sachs Group started coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective for the company. Sanford C. Bernstein started coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective for the company. Finally, William Blair started coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating for the company.

Kenvue Trading Down 1.1 %

Shares of NYSE:KVUE opened at $19.36 on Friday. Kenvue has a 12-month low of $17.82 and a 12-month high of $27.80. The business has a 50 day moving average of $19.84 and a 200-day moving average of $20.15. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The company had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. The firm’s revenue was down 2.7% on a year-over-year basis. On average, equities analysts predict that Kenvue will post 1.15 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 4.13%. The ex-dividend date of this dividend was Tuesday, February 13th.

Institutional Investors Weigh In On Kenvue

A number of large investors have recently modified their holdings of KVUE. Clearstead Advisors LLC purchased a new position in Kenvue in the third quarter worth about $25,000. Planned Solutions Inc. purchased a new position in Kenvue in the fourth quarter worth about $27,000. AdvisorNet Financial Inc purchased a new position in Kenvue in the third quarter worth about $28,000. Global Retirement Partners LLC purchased a new position in Kenvue in the third quarter worth about $28,000. Finally, Venturi Wealth Management LLC purchased a new position in Kenvue in the third quarter worth about $28,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.